CoChat

Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging

Open access
Howes, Oliver, Marcinkowska, Julia, Turkheimer, Federico E., Carr, Richard · 2025 · Neuropsychopharmacology

The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.

Abstract

Synapses are implicated in many neuropsychiatric illnesses. Here, we provide an overview of in vivo techniques to index synaptic markers in patients. Several positron emission tomography (PET) tracers for synaptic vesicle glycoprotein 2 A (SV2A) show good reliability and selectivity. We review over 50 clinical studies including over 1700 participants, and compare findings in healthy ageing and across disorders, including addiction, schizophrenia, depression, posttraumatic stress disorder, and neurodegenerative disorders, including tauopathies, Huntington’s disease and α-synucleinopathies. These show lower SV2A measures in cortical brain regions across most of these disorders relative to healthy volunteers, with the most well-replicated findings in tauopathies, whilst changes in Huntington’s chorea, Parkinson’s disease, corticobasal degeneration and progressive supranuclear palsy are predominantly subcortical. SV2A PET measures are correlated with functional connectivity across brain networks, and a number of other measures of brain function, including glucose metabolism. However, the majority of studies found no relationship between grey matter volume measured with magnetic resonance imaging and SV2A PET measures. Cognitive dysfunction, in domains including working memory and executive function, show replicated inverse relationships with SV2A measures across diagnoses, and initial findings also suggest transdiagnostic relationships with mood and anxiety symptoms. This suggests that synaptic abnormalities could be a common pathophysiological substrate underlying cognitive and, potentially, affective symptoms. We consider limitations of evidence and future directions; highlighting the need to develop postsynaptic imaging markers and for longitudinal studies to test causal mechanisms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41386-024-01943-x

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Structure of a typical synapse and synaptic vesicle. a Overview of the synapse, showing the presynaptic terminal with vesicles containing neurotransmitter, synaptic gap, and the postsynaptic density with neurotransmitter binding to receptors. Action potentials (arrow) trigger vesicular fusion with the presynaptic membrane to release neurotransmitter (b), which then diffuses across the synaptic gap to bind to receptors in the post-synaptic density. b Representation of a vesicle primed for fusion with the presynaptic membrane, showing key vesicle proteins. SNARE soluble N-ethylamide-sensitive factor attachment protein receptor complex.
Fig. 1 Structure of a typical synapse and synaptic vesicle. a Overview of the synapse, showing the presynaptic terminal with vesicles containing neurotransmitter, synaptic gap, and the postsynaptic density with neurotransmitter binding to receptors. Action potentials (arrow) trigger vesicular fusion with the presynaptic membrane to release neurotransmitter (b), which then diffuses across the synaptic gap to bind to receptors in the post-synaptic density. b Representation of a vesicle primed for fusion with the presynaptic membrane, showing key vesicle proteins. SNARE soluble N-ethylamide-sensitive factor attachment protein receptor complex.CC BY · PubMed Central
Fig. 2 Colocalisation of SV2A and synaptophysin in the baboon brain. a High-power confocal microscopy of 4’,6-diamidino-2-phenylindole (DAPI), synaptophysin (SYN), and synaptic vesicle glycoprotein 2A (SV2A) in the grey matter of the baboon brain. Labelling for SYN and SV2A is evident as punctate staining in the neuropil, particularly surrounding neuronal cell bodies and proximal dendrites (yellow arrow), but absent in neuronal cell bodies (white arrows). Nuclei are indicated by the DAPI stain in blue. b Correlation between in vitro SV2A and in vitro SYN density in grey matter regions determined using Western blot analyses. Data are nine brain regions. Figure and legend reproduced from Finnema et al. with permission (2016) [47]. GM grey matter, OD optical density.
Fig. 2 Colocalisation of SV2A and synaptophysin in the baboon brain. a High-power confocal microscopy of 4’,6-diamidino-2-phenylindole (DAPI), synaptophysin (SYN), and synaptic vesicle glycoprotein 2A (SV2A) in the grey matter of the baboon brain. Labelling for SYN and SV2A is evident as punctate staining in the neuropil, particularly surrounding neuronal cell bodies and proximal dendrites (yellow arrow), but absent in neuronal cell bodies (white arrows). Nuclei are indicated by the DAPI stain in blue. b Correlation between in vitro SV2A and in vitro SYN density in grey matter regions determined using Western blot analyses. Data are nine brain regions. Figure and legend reproduced from Finnema et al. with permission (2016) [47]. GM grey matter, OD optical density.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 160 references

Research works printed but not linked: 4

  1. Cai H, Mangner T, Muzik O, Chugani H. Radiosynthesis and preliminary evaluation of 11C-levetiracetam for PET imaging of SV2A expression. Soc Nuclear Med. 2014; 55:1795.
  2. Cai Z, Drake L, Naganawa M, Najafzadeh S, Pracitto R, Lindemann M. et al. First-in-human study of [18F] SynVesT-2, a novel SV2A radioligand with fast kinetics and high specific binding signals. Soc Nuclear Med. 2020;61:462 · DOI · Paper page
  3. Onwordi EC, Whitehurst T, Shatalina E, Mansur A, Arumuham A, Osugo M, et al. Synaptic Terminal Density Early in the Course of Schizophrenia: an in vivo UCB-J Positron Emission Tomographic Imaging Study of Synaptic Vesicle Glycoprotein 2A (SV2A). Biol Psychiatry 2023;S0006-3223:01353–7.
  4. Reichert JS. SV2A-just a synaptic vesicle protein? Unravelling the interaction of SV2A and mitochondria in the pathogenesis and therapy of Morbus Alzheimer. Dissertation, Mainz, Johannes Gutenberg-Universität Mainz, 2022;2022.

Cited by

See all 42

Metadata

Authors
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R.
Affiliations
King's College London (GB)
Corresponding author
Howes, Oliver
Venue
Neuropsychopharmacology
Published
2024-08-12
Volume
50
Issue
1
Pages
164-183
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W4401527108
Cited by
34
References
161
Citations by year
2026: 19 · 2025: 14 · 2024: 1
FWCI
2.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, cc-by)
Funders
  • RCUK | Medical Research Council (MC_U120097115, MR/W005557/1, MR/V013734/1)
  • Wellcome Trust (094849/Z/10/Z)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
synaptic markers, SV2A, mental illness, neurological disorders, tauopathy, Huntington's disease, synucleinopathies, Parkinson's disease, corticobasal degeneration, progressive supranuclear palsy, schizophrenia, depression, post-traumatic stress disorder, addiction, functional connectivity, glucose metabolism, cognitive impairment, transdiagnostic mechanisms, healthy aging
MeSH terms
Animals, Mental Disorders, Brain, Humans, Nervous System Diseases, Synapses, Positron-Emission Tomography, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging. https://app.cochat.ai/papers/10.1038/s41386-024-01943-x
The paper
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025). Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging. Neuropsychopharmacology. https://doi.org/10.1038/s41386-024-01943-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.